LABORATORY OF PROTEOMICS
NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE, LISBON, PORTUGAL
The ultimate mission of the laboratory is to provide the society with new diagnostic, prognostic and/or follow-up tools based on proteomics allowing clinicians to truly tailor therapy.
Main Research Interest
• Translational proteomics: biomarker discovery and validation for Chronic Lung Diseases (e.g., Cystic Fibrosis, Asthma, COPD, Obstructive Sleep Apnea).
• Pharmacoproteomics (e.g., global drug profiling) and Toxicoproteomics (e.g., molecular effects of environmental tobacco smoke exposure (TSE)).
• Development of proteomics-based technologies for biomarker discovery, validation and translation [e.g., mass spectrometric immunoassay – MSIA)
Research Support Services / Collaborations
We have established a complete pipeline for analysis of clinical samples (plasma, blood cells, tissue) using state of art proteomics-based technologies (2-DIGE, LC/MS/MS, MSIA) and Mass Spectrometry (MS) instruments (MALDI-TOFTOF, Orbitrap) which supports all quantitative proteomics-based technologies. This pipeline is designed to disease biomarker discovery (clinical proteomics) or global drug / TSE profiling (pharmacoproteomics/toxicoproteomics) but it can be used in any proteomics-based project.